Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.23p -3.22% 6.92p 6.90p 6.94p 7.15p 6.92p 7.15p 895,710 12:37:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.4 -4.8 -3.2 - 14.16

Futura Medical Share Discussion Threads

Showing 16151 to 16174 of 16425 messages
Chat Pages: 657  656  655  654  653  652  651  650  649  648  647  646  Older
DateSubjectAuthorDiscuss
24/7/2018
11:38
T&R is a subsidiary of Stada that has it’s own competing (?) diclofenac gel. For being so enthousiatic about FUM’s gel they sure don’t seem to be in a hurry to get regulatory approval. T&R has been working on getting that approval since Q4 2016. I feel that’s (too) long to be really serious.
greedfear
24/7/2018
10:35
Thanks JJ, that's what I was remembering. It's not strictly quite the same as clinical efficacy but it'd be rather surprising if the increased bioavailability did not translate into increased efficacy at least in soft tissues. Joints might be more of a challenge. I note that the recent RNS includes: "TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys(R) delivery system, will be launched, once approved, as an over-the-counter and general sales ledger product for the local symptomatic relief of pain and inflammation in: -- trauma of the tendons, ligaments, muscles and joints, e.g. from sprains, strains and bruises -- localised forms of soft tissue rheumatism. " [my bold] So they are including joints there but I wonder whether superior efficacy in joints is proven. Even if not it should sell.
rrr
24/7/2018
09:26
Trials were completed in 2015.Market-leading clinical trial resultsEarly completed in vitro and in vivo studies showed significant superiority in terms of skin penetration of the diclofenac molecule for TPR100 compared with other commercially available products. These studies showed that TPR100 achieved up to 40 times higher bioavailability than those achieved by other commercially available products with none of the side effects which can be seen with oral NSAID products.
j777j
24/7/2018
08:51
Thanks suoerg1: 'I'd have to have a look to see if it outperforms the world number 1 out that's what they were indicating some time back.' That's what I was remembering too. I do seem to remember also that with the Dermasys formulation absorption was very much better than existing formulations so one would expect superior clinical performance - but whether that's demonstrated I'm now unsure. Please let us know if you find anything more on this.
rrr
24/7/2018
08:39
guessing it is disappointing but can be explained by the BoD having a long history of signing many distributorship deals which amount to nothing in the end - hence the share price performance, or lack of, I should say
mikethebike4
24/7/2018
08:36
rrr Yes it takes a long time then add on about 18 months (previous FUM chat) for preparation of a market launch. The clock stops on questions re the 210 days. It didn't talk outperform in the RNS just Futura has achieved statistically significant pain relief in a clinical study compared with placebo for TPR100, which is a non-steroidal anti-inflammatory drug ("NSAID") using diclofenac as its active ingredient. I'd have to have a look to see if it outperforms the world number 1 out that's what they were indicating some time back.
superg1
23/7/2018
23:22
Positively delighted as news is a bonus and no share price movement as the really important RNS will contain med 2002 details.Jo Stalin no boom expected till med 2002 licensing deal or TTT is encapsulated in the RNs
shakin not stirred
23/7/2018
15:39
Given that we had been waiting on an update confirming that T&R had completed the application to UK Medicines and Healthcare products Regulatory Agency it's very disappointing to see the complete lack of positive share price action. The RNS brings the commercial release of TPR100 considerably closer and the importance of the RNS seems to have completely been overlooked.
guessing
23/7/2018
14:13
Was that it? The Booooommmmm was deafening!
joestalin
23/7/2018
13:27
They will receive milestone payments well before then. More importantly they will have another product commercialised and more to follow according to today's Rns. 'The co has a habit of clusters of news. I won't risk being out of this stock on The basis a med2002 deal will see the share price multiply. Tick tock..
j777j
23/7/2018
12:36
I guess it's widely seen as yet another jam tomorrow RNS. As it is. Track record of actually getting anything to market and selling it is poor. I expect this will be approved, but that could be 30 weeks plus away (but might be sooner) and then we wait to see if it actually gets to the shops this time. If marketed well at a reasonable price I think it should sell well in time as it does seem to have considerable advantages over existing. If all that happens then FUM should make some money at last. But you can see why people aren't leaping in today. rrr
rrr
23/7/2018
11:37
Well the market is clearly underwhelmed by the RNS.
weildy2
23/7/2018
10:56
If this is solely a UK application then it seems that: "The application process takes up to 210 days, excluding time taken to provide further information or data required." hTTps://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk#national
rrr
23/7/2018
09:41
You may well be right S0llis! Trouble is at the moment she'd find it difficult to get hold of any.
rrr
23/7/2018
09:39
My post was a light-hearted way of saying that potential and actual are different things. We have heard from Futura about potential many times but actual sales and income have been minimal.
rrr
23/7/2018
09:37
rrr Not too sure of that. I think she would have needed an adequate supply of MED2002 and occasional CSD500 to raise her partners' performance to hers.
s0lis
23/7/2018
09:17
"An ounce of performance is worth pounds of promises." - Mae West. I don' think she'd have invested in Futura.
rrr
23/7/2018
09:04
j7 "TPR100 is licensed in the UK to Thornton & Ross, one of the UK's largest consumer healthcare companies and a subsidiary of STADA. Thornton & Ross holds exclusive rights to manufacture, distribute and market TPR100 in the UK for the lifetime of the product's patents, which run to 2028 in the UK." let's hope they come up with the goods market-wise rather than just sit on it like so many so-called distributors Futura have agreements with ! just remember the CSD500/Blue Diamond debacle
mikethebike4
23/7/2018
08:37
More news to follow.....TPR100 has the potential to be a best-in-class treatment in which the topical formulation and efficacy profile very successfully meet patient needs. We continue in commercial discussions with several potential distribution partners for territories outside of the UK.So pain gel market worth nearly $3 billionMed2002 potentially $1 billion salesWatch this space :-)~
j777j
23/7/2018
08:16
Chart looks nice if you have a short position. What a dog this is.
greedfear
23/7/2018
08:15
Yes, well the market seems to be excited too. No further updates? Hm.
greedfear
23/7/2018
08:00
Dec 2017".......This means that the best-in-class topical treatment should be the first choice for doctors in the initial treatment of pain and therefore represents a substantial opportunity in a market with global sales estimated at US$2.9 billion."
j777j
23/7/2018
07:48
a small step - lets hope it gets to market quickly and earns us a few bob !
mikethebike4
23/7/2018
06:34
Good news.
rrr
Chat Pages: 657  656  655  654  653  652  651  650  649  648  647  646  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20181114 02:11:23